Abstract
Twenty-five (71%) of 35 patients with cutaneous T-cell lymphoma (CTCL) treated with ultraviolet B (UVB) phototherapy achieved a total remission. Median time to remission was 5 months, and median duration of the remission was 22 months. Twenty-five (83%) of patients with disease limited to patches (Stage I) achieved remission, whereas none of the patients with plaque level disease (Stage II) achieved remission. Of the 25 patients who achieved complete remission, five (20%) had a recurrence of CTCL. These results suggest that UVB phototherapy is an effective treatment for patients with early stage I disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abel EA, DG Deneau, EM Farber et al., 1981. PUVA treatment of erythrodermic and plaque type mycosis fungoides. J. Am. Acad. Dermatol., 4: 423–429.
Aberer W, G Schuler, G Stingi et al., 1981. UV light depletes surface markers of Langer-hans cells. J. Invest. Dermatol., 76: 202–210.
Ansel JC, TA Luger and I Green, 1983. The effect of in vitro and in vivo UV irradiation on the production of ETAF activity by human and murine keratinocytes. J. Invest. Dermatol., 81: 519–523.
Austad J and LR Braathen, 1985. Effect of UVB on alloactivating and antigen-presenting capacity of human epidermal Langerhans cells. Scand. J. Immunol., 21: 417–423.
Bunn PA, AB Fischmann, GP Schechter et al., 1979. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas. Cancer Treat. Rep., 63: 713–717.
Bunn PA Jr and SI Lamberg, 1979. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat. Rep., 63: 725–728.
Bunn PA and DA Norris, 1990. The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J. Invest. Dermatol., 95: 209S-212S.
Edelson R, C Berger, F Gasparro et al., 1987. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N. Engl. J. Med., 316: 297–303.
Gilchrest BA, 1979. Methoxsalen photochemotherapy for mycosis fungoides. Cancer Treat. Rep., 63: 663–667.
Grozea PN, SE Jones, EM McKelvey et al., 1979. Combination chemotherapy for mycosis fungoides: A Southwest oncology group study. Cancer Treat. Rep., 63: 647–653.
Hamminga L, J Hermans, EM Noordijk et al., 1982. Cutaneous T-cell lymphoma: Clinoco-pathological relationships, therapy and survival in ninety-two patients. Br. J. Dermatol., 107: 145–156.
Hamminga B, EM Noordijk and WA van Vloten, 1982b. Treatment of mycosis fungoides: Total skin electron beam irradiation vs. topical mechlorethamine therapy. Arch. Dermatol., 118: 150–153.
Hoppe RT, EA Abel, DG Deneau et al., 1987. Mycosis fiingoides: Management with topical nitrogen mustard. J. Clin. Oncol., 5: 1796–1803.
Hoppe RT, RS Cox, Z Fuks et al., 1979. Electron-beam therapy for mycosis fungoides: The Stanford University experience. Cancer Treat. Rep., 63: 691–700.
Hostetler LW, HN Ananthaswamy and ML Kripke, 1986. Generation of tumor-specific transplantation antigens by UV radiation can occur independently of neoplastic transforma tion. J. Immunol., 137: 2721–2725.
Kaplan EH, ST Rosen, DB Norris et al., 1990. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J. Natl. Cancer Inst., 82: 208–212
Knox SJ, R Levy, S Hodgkinson et al., 1991. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fiingoides. Blood, 77: 20–30.
Kaye FJ, PA Bunn, Jr, SM Steinberg et al., 1989. A randomized trial comparing combina tion electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N. Engl. J. Med., 321: 1784–1790.
Kupper TS, AO Chua, P Flood et al., 1987. Interleukin 1 gene expression in cultured human keratinocytes is augmented by ultraviolet irradiation. J. Clin. Invest., 80: 430–436
Kuzel TM, R Gilyon R, E Springer et al., 1990. Interferon alfa-2a combined with photo therapy in the treatment of cutaneous T-cell lymphoma. J. Natl. Cancer Inst., 82: 203–207.
Le Bourgeois JP, E Haddad, G Mannello et al., 1987. The indications for total cutaneous electron beam radiation therapy of mycosis fungoides. Int. J. Radiat. Oncol. Biol. Phys., 13: 189–193.
Lowe NJ, DJ Cripps, PA Dutton PA et al., 1979. Photochemotherapy for mycosis fungoi des: A clinical and histologic study. Dermatol., 115: 50–53.
Maddox AM, BD Kahan, S Tuker, et al., 1985. Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporin. J. Am. Acad. Dermatol., 12: 952–956.
McDonald CJ and JR Bertino, 1978. Treatment of mycosis fungoides lymphoma: Effectiveness of infusions of methotrexate followed by oral citrovorum factor. Cancer Treat. Rep., 62: 1009–1014.
Merlo CJ, RT Hoppe, E Abel et al., 1987. Extracutaneous mycosis fungoides. Cancer, 60: 397–402.
Milstein HJ, EC Vonderheid, EJ Van Scott et al., 1982. Home ultraviolet phototherapy of early mycosis fungoides: Preliminary observations. J. Amer. Acad. Dermatol., 6: 355–362.
Molin L, K Thomsen, G Volden et al., 1987. Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm. Venereol. (Stockh), 67: 179–182.
Moreland AA, DB Robertson and LT Heffner, 1985. Treatment of cutaneous T cell lymphoma with cyclosporin A. J. Am. Acad. Dermatol., 12: 886–887.
Nisce LZ and B Safai, 1979. Once weekly total skin electron beam therapy for mycosis fungoides. Cancer Treat. Rep., 63: 633–638.
Norris DA, MB Lyons, MH Middleton et al., 1990. Ultraviolet radiation can either suppress or induce expression of intercellular adhesion molecule 1 (ICAM-1) on the surface of cultured human keratinocytes. J. Invest. Dermatol., 95: 132–138.
Olsen EA, ST Rosen, RT Vollmer et al., 1989. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J. Am. Acad. Dermatol., 20: 395–407.
Oxholm A, P Oxholm, B Staberg et al., 1988. Immunohistological detection of interleukin I-like molecules and tumour necrosis factor in human epidermis before and after UVB-irra-diation in vivo. Br. J. Dermatol., 118: 369–376.
Price NM, RT Hoppe and DG Deneau DG, 1983. Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer, 52: 2214–2219.
Powell FC, GT Siegel and SA Muller, 1984. Treatment of parapsoriasis and mycosis fungoides: The role of psoralen and long-wave ultraviolet A (PUVA). Mayo Clin. Proc., 59: 538–546.
Ramsay DL, PS Halperin and A Zeleniuch Jacquotte, 1988. Topical mechlorethamine therapy for early stage mycosis fungoides. J. Am. Acad. Dermatol., 19: 684–691.
Rasanen L, T Reunala, M Lehto et al., 1989. Immediate decrease in antigen-presenting function and delayed enhancement of interleukin-I production in human epidermal cells after in vivo UVB irradiation. Br. J. Dermatol., 120: 589–596.
Roenigk HH, TM Kuzel, AP Skoutelis et al., 1990. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J. Invest. Dermatol., 95: 198S-205S.
Rosenbaum MM, HH Roenigk, WA Caro et al., 1985. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. J. Am. Acad. Dermatol., 13: 613–622.
Rowden G, TM Phillips, MG Lewis et al., 1979. Target role of Langerhans cells in mycosis fungoides: Transmission and immuno-electron microscope studies. J. Cut. Pathol., 6: 364–382.
Sanchez JL and AB Ackerman, 1979. The patch stage of mycosis fungoides: Criteria for histologic diagnosis. Am. J. Dermatopathol., 1: 5–26.
Sauder DN, FP Noonan, EC De Fabo et al., 1983. Ultraviolet radiation inhibits alloantigen presentation by epidermal cells: Partial reversal by the soluble epidermal cell product, epidermal cell-derived thymocyte-activating factor (ETAF). J. Invest. Dermatol., 80: 485–489.
Slevin NJ, V Blair and ID Todd, 1987. Mycosis fungoides — Response to therapy and survival patterns in 85 cases. Br. J. Dermatol., 116: 47–53.
Stingi G, LA Gazze-Stingl, W Aberer et al., 1981. Antigen presentation by murine epidermal Langerhans cell and its alteration by ultraviolet B light. J. Immunol., 127: 1707–1713.
Tadros AAM, BS Tepperman, WM Hryniuk et al., 1983. Total skin electron irradiation of mycosis fungoides: Failure analysis and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys., 9: 1279–
Tirelli U, A Carbone, A Veronesi et al., 1982. Combination chemotherapy with cyclophos phamide, vincristine, and prednisone (CVP) in TNM — classified stage IV mycosis fungoides. Cancer Treat. Rep., 66: 167–169
Tron VA, D Rosenthal and DN Sauder, 1988. Epidermal interleukin-1 is increased in cutaneous T-cell lymphoma. J. Invest. Dermatol., 90: 378–381.
Urbanski A, T Schwarz, P Neuner et al., 1990. Ultraviolet light induces increased circula ting interleukin-6 in humans. J. Invest. Dermatol., 94: 808–811.
Van Vloten WA, H De Vroome and EM Noordijk, 1985. Total skin electron beam irradiation for cutaneous T-cell lymphoma (mycosis fungoides). Br. J. Dermatol., 112: 697–702.
Vegna ML, G Papa, D Defazio et al., 1990. Interferon alpha-2a in cutaneous T-cell lymphoma. Eur. J. Haematol., 45: Suppl. 52: 32–35
Volden G and TE Larsen, 1978. Remissions of mycosis fungoides induced by nitrogen mustard (HN2). Dermatologica, 156: 129–141.
Vonderheid EC, ET Tan, AF Kantor et al., 1989. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J. Am. Acad. Dermatol., 20: 416–428.
Vonderheid EC, EJ Van Scott, PE Wallner et al., 1979. A 10 year experience with topical mechlorethamine for mycosis fungoides: Comparison with patients treated by total-skin electron beam radiation therapy. Cancer Treat. Rep., 63: 681–689.
Zachariae H, E Grunnet, K Thestrup-Pedersen et al., 1982. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor in mycosis fungoides. Acta Derm. Venereol., 62: 162–164.
Zachariae H, K Thestrup-Pedersen and H Sogaard, 1985. Topical nitrogen mustard in early mycosis fungoides. Acta Dermatol. Venereol. (Stockh)., 65: 53–58
Zakem MH, BR David, DJ Adelstein et al., 1986. Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin and methotrexate with topical nitrogen mustard (BAM-M). Cancer, 58: 2611–2616.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ramsay, D.L., Lish, K.M., Yalowitz, C.B., Soter, N.A. (1994). Response of Early Stage Cutaneous T-Cell Lymphoma to Ultraviolet B Phototherapy. In: Lambert, W.C., Giannotti, B., van Vloten, W.A. (eds) Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin. NATO ASI Series, vol 265. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1861-7_39
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1861-7_39
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5756-8
Online ISBN: 978-1-4615-1861-7
eBook Packages: Springer Book Archive